anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety and effectiveness of DYMISTA for seasonal allergic rhinitis have been established in pediatric patients aged 6 years and older. Use of DYMISTA for this indication in pediatric patients 6 to 11 years of age is supported by evidence from controlled clinical trials (416 patients 6 to 11 years of age with allergic rhinitis were treated with DYMISTA) [see Adverse Reactions (6.1) and Clinical Studies (14)].

Sixty-one patients ages 4-5 years of age were treated with DYMISTA in the pediatric studies described above. Safety findings in children 4-5 years of age were similar to those in children 6-11 years of age, but effectiveness has not been established.

Safety and effectiveness of DYMISTA have not been established in pediatric patients below the age of 4 years.

Controlled clinical studies have shown that nasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving nasal corticosteroids, including DYMISTA, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks/benefits of treatment alternatives.
Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, reduce the starting dose [see Dosage and Administration (2)] .   
  
Ramipril can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient's serum potassium frequently.
A  Chrysanthemum zawadskii  (abbrev. to “ Chrysanthemum ”) extract with adjusted contents of each of indicator components of  Chrysanthemum zawadskii  (abbrev. to “ Chrysanthemum ”) is disclosed. The indicator components include linarin, chlorogenic acid and isochlorogenic acid. Also disclosed is a method for setting a standard for contents of the indicator components by identifying causes of the difference in properties of the  Chrysanthemum  extract or raw material and standardizing a preparation process from the analyzed causes of the difference in properties, to obtain a  Chrysanthemum  extract standardized by setting a content range of each indicator component in the  Chrysanthemum  raw material. Uses of the extract or a composition containing the extract are disclosed.
Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
The present invention relates to a traditional Chinese medicine composition for treating diabetic heart disease, which takes more than 10 Chinese herbal medicines of heterophylly falsestarwort root, dwarf lilyturf tuber, Chinese magnoliavine fruit, membranous milkvetch root etc. as the raw materials. The invention has the effects of benefiting qi, nourishing yin, activating blood circulation and dredging collaterals. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for treating diabetic heart disease. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
A computerized method and system for reducing the number of false-positive detections of nodule candidates in the detection of abnormalities in digital chest radiography. The image is initially subjected to an image difference technique where the detection sensitivity is increased so as to avoid missing small nodules which might otherwise go undetected. Such a technique tends to increase the number of false-positives, however, leading to possible incorrect diagnoses of the radiographs. To reduce the number of false-positives, feature extraction techniques are applied to grown regions around the nodule candidates, in order to provide computer generated information concerning the candidates. A data base of parameters common to false-positives is compared to calculated parameters of a candidate of interest. The candidates with grown region parameters within the data base range common to false-positives are eliminated as being probable false-positive detections due to normal background anatomical features.
PURPOSE OF REVIEW: This review considers recent observations on vestibular syncope in terms of clinical features, laboratory findings, and potential mechanisms.
RECENT FINDINGS: Vestibular syncope, potentially associated with severe fall-related injuries, may develop multiple times in about one-third of patients. Meniere's disease and benign paroxysmal positional vertigo are the most common causes of vestibular syncope, but the underlying disorders remain elusive in 62% of cases with vestibular syncope. The postictal orthostatic blood pressure test exhibits a lower diagnostic yield. Vestibular function tests, such as cervical vestibular-evoked myogenic potentials and video head impulse tests, can reveal one or more abnormal findings, suggesting compensated or ongoing minor vestibular dysfunctions. The pathomechanism of syncope is assumed to be the erroneous interaction between the vestibulo-sympathetic reflex and the baroreflex that have different operating mechanisms and action latencies. The central vestibular system, which estimates gravity orientation and inertia motion may also play an important role in abnormal vestibulo-sympathetic reflex.
SUMMARY: Vestibular disorders elicit erroneous cardiovascular responses by providing false vestibular information. The results include vertigo-induced hypertension or hypotension, which can ultimately lead to syncope in susceptible patients.
BACKGROUND: Crouch gait, or flexed knee gait, represents a common gait pattern in patients with spastic bilateral cerebral palsy (CP). Distal femoral extension and/or shortening osteotomy (DFEO/DFSO) and patellar tendon advancement (PTA) can be considered as viable options when knee flexion contractures are involved. Better outcomes have been reported after a combination of both, independently of the presence of knee extensor lag. In this study, we evaluated the clinical and kinematic outcomes of these procedures.
PATIENTS AND METHODS: We reviewed a cohort of 52 limbs (28 patients) who were treated for crouch gait by DFEO/DFSO alone (group 1, n = 15) or DFEO/DFSO + PTA (group 2, n = 37) as a part of single event multilevel surgery (SEMLS). The mean age at surgery was 14 years, and the mean follow-up time was 18 months. The physical examination data and three-dimensional standardized gait analysis were collected and analyzed before the surgery and postoperatively.
RESULTS: Overall knee range of motion improved in all limbs. The knee flexion decreased significantly in both groups at initial, mid, and terminal stance. Hip flexion significantly decreased in mid-stance for limbs in group 2. Both clinical and gait parameters were most improved in limbs who underwent DFEO/DFSO + PTA. Increased pelvic tilt was observed in both groups after surgery.
CONCLUSION: Although DFEO/DFSO alone was successful in correcting knee flexion contractures, PTA has helped to improve knee extensor lag and knee extension during gait.
LEVEL OF EVIDENCE: Therapeutic level IV.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to neurology, physiotherapy. The method includes cryomassage of lumbosacral spine and sinusoidal modulated current electrophoresis in the erect mode with paravertebral location of the electrodes. In addition, cryomassage affected limb is made. During cryomassage skin is cooled till +10 +12 C. Exposure during 10 minutes in one area. In 30-40 minutes electrophoresis is made. For electrophoresis adgelona solution with a concentration of 10-12 mol/liter is used. For it a pad soaked in 5 ml of adgelona is placed under the electrode-cathode. For the used mode work I a frequency modulation (FM) is 100 Hz, and modulation depth (MD) is 50% and for III mode of work with FM is 80 Hz and MD is 50%. The duration of half-periods is 2 and 3 sec. Duration of implementation of each mode if work is 7 minutes. A course of treatment consists of 10-12 procedures carried out daily. ^ EFFECT: method prevents development of epidural and perineural fibrosis, reduces the treatment period and increases the duration of remission. ^ 2 ex, 1 tbl
Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, the dose of IPT-A will be increased by scheduling sessions twice per week for 4 weeks (16 sessions total).
PROBLEM TO BE SOLVED: To provide a method for mass-producing a dried powder having good quality of a plant leaf such as a carrot leaf. SOLUTION: (1) The method for mass-producing the dried powder of the plant leaf comprises heated-air drying of an object to be dried (a raw material leaf) until the final high temperature is reached while repeating a cycle of raising temperature to a low intermediate temperature, exhausting a gas and reducing the temperature without suddenly heating the object to be dried (the raw material leaf) to a high temperature. (2) The method comprises introducing a primary drying stage with natural draft as a former stage of the cycle of raising the temperature-exhausting the gas and reducing the temperature. The primary drying stage functions as a temporary preserving part after completing the primary drying.  Thereby, (1) the quality of the dried product can be stabilized and improved and (2) the process time of the heated-air drying stage can remarkably be shortened to remarkably increase the throughput, and excessive raw material leaf can effectively be preserved and used for mass production. (3) A way for wide application of the resultant effective dried powder with good quality to deodorizing, antimicrobial and other hygienic purposes is developed.
The invention discloses a novel oral solid medicinal composition. The novel oral solid medicinal composition is an oral preparation prepared from hydrochlorothiazide, levamlodipine besylate, candesartan cilexetil and pharmaceutically acceptable auxiliary materials. The novel oral solid medicinal composition can be processed into tablets, capsules and the like. Specifically, the novel oral solid medicinal composition comprises: be weight, 5 to 25 parts of hydrochlorothiazide, 2.5 to 5 parts of levamlodipine besylate, 4 to 20 parts of candesartan cilexetil, 30 to 60 parts of microcrystalline cellulose, 30 to 60 parts of compressible starch, 30 to 50 parts of crosslinked polyvinylpyrrolidone, 1 to 2 parts of silica and 0.5 to 2 parts of magnesium stearate. The novel oral solid medicinal composition has a scientific and reasonable formula, low auxiliary material content and high bioavailability. Therefore, the novel oral solid medicinal composition is a drug of first choice for the treatment of hypertension.
This invention relates to a veterinary antiseptic solution having three sources of iodine including elemental iodine, iodide salt and iodophor. The solution also includes at least one solvent such as alcohol, glycol or water. The solution is below the threshold concentration for elemental iodine of the List I controlled substances. The elemental iodine offers a rapid kill for bacteria. The iodophor offers lasting antibacterial properties. The iodide salt solubilizes elemental iodine and stabilizes the solution. The antiseptic solution forms a waterproof bandage with active antimicrobial properties when the alcohol dries.
Recent advances in human genetics have shed light on the genetic factors contributing to inflammatory diseases, particularly Crohn's disease (CD), a prominent form of inflammatory bowel disease. Certain risk genes associated with CD directly influence cytokine biology and cell-specific communication networks. Current CD therapies primarily rely on anti-inflammatory drugs, which are inconsistently effective and lack strategies for promoting epithelial restoration and mucosal balance. To understand CD's underlying mechanisms, we investigated the link between CD and the FGFR1OP gene, which encodes a centrosome protein. FGFR1OP deletion in mouse intestinal epithelial cells disrupted crypt architecture, resulting in crypt loss, inflammation, and fatality. FGFR1OP insufficiency hindered epithelial resilience during colitis. FGFR1OP was crucial for preserving non-muscle myosin II activity, ensuring the integrity of the actomyosin cytoskeleton and crypt cell adhesion. This role of FGFR1OP suggests that its deficiency in genetically predisposed individuals may reduce epithelial renewal capacity, heightening susceptibility to inflammation and disease.
Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
BACKGROUND: Cuproptosis is a type of cell death characterized by excessive copper-lipid reactions in the tricarboxylic acid cycle, resulting in protein toxicity stress and cell death. Although known as a cuproptosis inhibitor through CRISPR-Cas9 screening, the role of cyclin-dependent kinase inhibitor 2A (CDKN2A) in cuproptosis resistance and its connection to tumor development remains unclear.
METHODS: In this study, we combined single-cell sequencing, spatial transcriptomics, pathological image analysis, TCGA multi-omics analysis and in vitro experimental validation to comprehensively investigate CDKN2A distribution, expression, epigenetic modification, regulation and genomic features in colorectal cancer cells. We further explored the associations between CDKN2A and cellular pathway, immune infiltration and spatial signal communication.
RESULTS: Our findings showed an increasing trend in cuproptosis in the trajectory of tumor progression, accompanied by an upward trend of CDKN2A. CDKN2A underwent transcriptional activation by MEF2D and via the SNHG7/miR-133b axis, upregulating glycolysis, copper metabolism and copper ion efflux. CDKN2A likely drives epithelial-mesenchymal transition (EMT) and progression by activating Wnt signaling. CDKN2A is associated with high genomic instability and sensitivity to radiation and chemotherapy. Tumor regions expressing CDKN2A exhibit distinctive SPP1+ tumor-associated macrophage (TAM) infiltration and MMP7 enrichment, along with unique signaling crosstalk with adjacent areas.
CONCLUSIONS: CDKN2A mediates cuproptosis resistance through regulating glycolysis and copper homeostasis, accompanied by a malignant phenotype and pro-tumor niche. Radiation and chemotherapy are expected to potentially serve as therapeutic approaches for cuproptosis-resistant colorectal cancer with high CDKN2A expression.
The incidence of diabetes and related mortality rate increase yearly in modern cities. Additionally, elevated glucose levels can result in an increase of reactive oxygen species (ROS), ferroptosis, and the disruption of protective pathways in the heart. These factors collectively heighten the vulnerability of diabetic individuals to myocardial ischemia. Reperfusion therapies have been effectively used in clinical practice. There are limitations to the current clinical methods used to treat myocardial ischemia-reperfusion injury. As a result, reducing post-treatment ischemia/reperfusion injury remains a challenge. Therefore, efforts are underway to provide more efficient therapy. Salvia miltiorrhiza Bunge (Danshen) has been used for centuries in ancient China to treat cardiovascular diseases (CVD) with rare side effects. Salvianolic acid is a water-soluble phenolic compound with potent antioxidant properties and has the greatest hydrophilic property in Danshen. It has recently been discovered that salvianolic acids A (SAA) and B (SAB) are capable of inhibiting apoptosis by targeting the JNK/Akt pathway and the NF-κB pathway, respectively. This review delves into the most recent discoveries regarding the therapeutic and cardioprotective benefits of salvianolic acid for individuals with diabetes. Salvianolic acid shows great potential in myocardial protection in diabetes mellitus. A thorough understanding of the protective mechanism of salvianolic acid could expand its potential uses in developing medicines for treating diabetes mellitus related myocardial ischemia-reperfusion.
Although many different techniques for opiate detoxification exist, the search continues for more effective approaches to reduce the duration and discomfort associated with opioid withdrawal. It has been shown that very low doses of naltrexone administered in the presence of opiates has analgesic and dependency reducing properties. The purpose of this study is to investigate the effects of very low doses of naltrexone administered during a methadone tapering schedule for opiate detoxification. In addition, this study will compare the effectiveness of two different dose regimens of naltrexone.

Participants in this double-blind study will be recruited among opioid dependent individuals already enrolled in a 6-day inpatient opioid detoxification program. Participants will be already receiving standard treatment to control discomfort during a methadone tapering schedule. Participants will be randomly assigned to one of three groups. Two of the groups will be given naltrexone; Group 1 will receive 0.125 mg each day, and Group 2 will receive 0.250 mg each day. Group 3 will receive a placebo. Participants will be evaluated upon enrollment for opiate addiction severity. They will continue to be evaluated daily for signs of withdrawal and salivary cortisol. An additional evaluation and urine test will be completed 1 day following discharge. Daily evaluations will take 15 minutes to complete. Seven days following discharge, participants will be contacted for a 20-minute phone interview. During the phone interview, participants will schedule an appointment to provide a final urine specimen for the detection of drugs of abuse.
Irinotecan Hydrochloride Injection, USP is an antineoplastic agent of the topoisomerase I inhibitor class.

Irinotecan Hydrochloride Injection, USP is supplied as a sterile, pale yellow, clear, aqueous solution. Each milliliter of solution contains 20 mg of irinotecan hydrochloride (on the basis of the trihydrate salt), 45 mg of sorbitol, NF, and 0.9 mg of lactic acid, USP and Water for Injection, USP. The pH of the solution has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide or hydrochloric acid. Irinotecan Hydrochloride Injection, USP is intended for dilution with 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion. The preferred diluent is 5% Dextrose Injection, USP.

Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as Camptotheca acuminata or is chemically synthesized.

The chemical name is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate. Its empirical formula is C33H38N4O6∙HCl∙3H2O and molecular weight is 677.19. It is slightly soluble in water and organic solvents. Its structural formula is as follows:

Irinotecan Hydrochloride
PURPOSE: A manufacturing method of purple corn extract is provided to cause no concern over side effects or toxicity and to mass produce the purple corn extract which has excellent disease preventing or treating effects against cancer, hypertension, diabetes, diabetic complication, and the like. CONSTITUTION: A manufacturing method of purple corn extract comprises extracting purple corn with C1-C4 level of low grade alcohol solvent having 5-80% concentration. 1:10-20 volume times of the C1-C4 level of low grade alcohol solvent is used based on the weight of the purple corn. The solvent additionally includes one or more acids selected from a group including hydrochloric acid, nitric acid, sulfamic acid, perchloric acid, acetic acid, formic acid, lactic acid, and oxalic acid. The solvent includes the 0.1-20% of acid. In the extraction step, the purple corn is extracted by the C1-C4 level of low grade alcohol solvent having a 5-80% concentration at 20-60 deg. Celsius for 4-24 hours. The extraction step is completed by ultrasonic wave extraction with a vibration intensity of 150-300 watts for 8-20 minutes. The ultrasonic wave extraction is performed for 9-16 minutes to increase overall yield and aldose reductase suppression ratio. [Reference numerals] (AA) Total anthocyanin contents(mg/g); (BB) Extraction time(hr); (CC) Extraction temperature(°C)
This is an open-label (all people know the identity of the intervention), single arm, prospective (study following participants forward in time), post-marketing, multi-center (when more than one hospital or medical school team work on a medical research study) study to evaluate the efficacy and safety of escitalopram in participants with MDD with associated anxiety symptoms. The duration of the study will be 24 weeks at a starting dose of escitalopram 10 milligram per day (mg/day). The dose will be flexibly adjusted (maximum 20 mg/day) after 2 weeks of treatment depending on Investigator's discretion. The study will consist of 9 visits: Baseline, Week 1, 2, 4, 8, 12, 16, 20 and 24. Assessments of efficacy and safety will be performed at each visit. The primary efficacy evaluation will be done by Montgomery-Asbery Depression Rating Scale (MADRS) and Hamilton Anxiety Scale(HAM-A). Participant's safety will also be monitored throughout the study.
Positional Release technique (PRT) is apply after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 900 and adds slight flexion or extension to fine-tune.